Dr. Andrew Campbell is a fellow in the University of Toledo’s Hematology-Oncology program. He has been placed on ...
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
Sonnet BioTherapeutics (SONN) announced the appointment of Stephen McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.